Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction
- PMID: 28803400
- DOI: 10.1007/s11897-017-0358-4
Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction
Abstract
Purpose of review: The use of biomarkers in heart failure (HF) is a rapidly changing field. The purpose of this review is to assess the current evidence of the use of biomarkers for risk stratification in patients with HF with preserved ejection fraction (HFpEF).
Recent findings: Despite differences in pathophysiology between HF with reduced ejection fraction and HFpEF, traditional HF biomarkers such as brain natriuretic peptide and troponin retain prognostic value in most HFpEF-specific populations. Biomarkers of key pathophysiologic components of HFpEF, such as myocardial fibrosis, remodeling, and systemic inflammation are also valuable prognostic markers. Further investigation into HF biomarkers may identify significant therapeutic targets for the treatment of HFpEF.
Keywords: Biomarkers; Heart failure; Prognosis; Risk stratification.
Similar articles
-
The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.Eur J Heart Fail. 2017 Dec;19(12):1638-1647. doi: 10.1002/ejhf.911. Epub 2017 Aug 28. Eur J Heart Fail. 2017. PMID: 28849609
-
BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study.Int J Cardiol. 2017 Apr 15;233:61-66. doi: 10.1016/j.ijcard.2017.01.130. Epub 2017 Jan 31. Int J Cardiol. 2017. PMID: 28185703 Free PMC article.
-
Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.Eur J Heart Fail. 2012 Dec;14(12):1338-47. doi: 10.1093/eurjhf/hfs130. Epub 2012 Aug 5. Eur J Heart Fail. 2012. PMID: 22869458
-
Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review.Cardiology. 2017;136(3):192-203. doi: 10.1159/000450573. Epub 2016 Oct 27. Cardiology. 2017. PMID: 27784010 Review.
-
Novel biomarkers in heart failure with preserved ejection fraction.Heart Fail Clin. 2014 Jul;10(3):471-9. doi: 10.1016/j.hfc.2014.04.005. Heart Fail Clin. 2014. PMID: 24975910 Review.
Cited by
-
Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE).J Clin Med. 2023 Apr 9;12(8):2790. doi: 10.3390/jcm12082790. J Clin Med. 2023. PMID: 37109127 Free PMC article.
-
Cardiotoxicity of Anticancer Therapeutics.Front Cardiovasc Med. 2018 Feb 7;5:9. doi: 10.3389/fcvm.2018.00009. eCollection 2018. Front Cardiovasc Med. 2018. PMID: 29473044 Free PMC article. Review.
-
Combination of Plasma Biomarkers and Clinical Data for the Detection of Myocardial Fibrosis or Aggravation of Heart Failure Symptoms in Heart Failure with Preserved Ejection Fraction Patients.J Clin Med. 2018 Nov 8;7(11):427. doi: 10.3390/jcm7110427. J Clin Med. 2018. PMID: 30413105 Free PMC article.
-
Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis.Clin Res Cardiol. 2021 Apr;110(4):579-590. doi: 10.1007/s00392-020-01801-y. Epub 2021 Jan 22. Clin Res Cardiol. 2021. PMID: 33481097 Free PMC article.
-
Higher cardiorespiratory fitness predicts long-term survival in patients with heart failure and preserved ejection fraction: the Henry Ford Exercise Testing (FIT) Project.Arch Med Sci. 2019 Mar;15(2):350-358. doi: 10.5114/aoms.2019.83290. Epub 2019 Mar 4. Arch Med Sci. 2019. PMID: 30899287 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous